文拉法辛缓释剂治疗广泛性焦虑症的临床研究

目的探讨文拉法辛缓释剂治疗广泛性焦虑症的临床疗效和安全性。方法将136例广泛性焦虑症患者随机分为文拉法辛缓释剂组68例和阿普唑仑组68例。怡诺思组治疗剂量75~150m g/d,阿普唑仑组为1.2~3.6m g/d,观察时间均为6周。治疗前与治疗第2、4、6周末采用汉密尔顿焦虑量表、焦虑自评量表、副反应量表评定临床疗效和副反应。结果两组疗效相当,差异无显著性（P〉0.05）;阿普唑仑组起效时间快于文拉法辛缓释剂组,但远期疗效差于文拉法辛缓释剂组;怡诺思组副反应明显少于阿普唑仑组（χ2=7.49,P〈0.01）。结论文拉法辛缓释剂治疗广泛性焦虑疗效肯定,安全性高,依从性好,值得临床推广应用。

The Clinical Study of Venlafaxine Extended-release in the Treatment of Patients with Generalized Anxiety Disorder

Objective To explore the clinical efficacy and safety of Venlafaxine extended-release in generalized anxiety disorder. Methods A total of 136 patients with generalized anxiety disorder were randomly divided into Venlafaxine and Alpralid group （each n= 68）. Dosage of the Venlafaxine extended-release was 75-150mg/d and the Alpralid 1.2-3.6mg/d for 6 weeks. Clinical efficacy and side effects were assessed using Hamilton Anxiety Rating Scale（HAMA）,the Self-rating Anxiety Scale（SAS） and the Treatment Emergent Symptom Scale（TESS） before treatment and at the ends of 2nd,4th and 6th week treatment. Results Efficacies of 2 groups were equivalent and difference wasn＇t significant （P〉0.05） Alpralid took effect faster than Venlafaxine extended-release,but its long term efficacy was poorer side effects of the Venlafaxine extended-release was significantly fewer than those of the Alpralid （x^2= 7.49,P〈0. 01 ）. Concl usion Venlafaxine extended-release has better efficacy,higher safety and compliance in the treatment of generalized anxiety disorder.